Medical Doctor Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Elizabeth Cathcart-Rake

Medical Oncology Rochester, MN Medical Doctor

NPI 1275876989 CMS profile 2036823

200 1St St Sw, Rochester, MN 55905

Open in the dashboard

General payments

$5,612

3 records reported · program years 2021–2023

Research payments

$1,900

Paid to them · 1 record reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,104,741 paid to institutions, not to them · program years 2019–2021

Through program year 2023, Elizabeth Cathcart-Rake of Rochester, MN is reported in the CMS Open Payments database as having received $5,612 across 3 general payments and $1,900 in research payments paid to them. Separately, studies naming them as principal investigator received $1,104,741 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 57th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,900 1
2022 Research $1,900 1
2021 General $3,712 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Cathcart-Rake
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Elizabeth Cathcart-Rake were reported at $0. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Elizabeth Cathcart-Rake Medical Oncology median Middle half National median
2019 $0 $968 $140–$6,658 $163
2020 $0 $747 $102–$5,891 $114
2021 $3,712 $430 $50–$4,098 $132
2022 $0 $812 $127–$4,907 $149
2023 $1,900 $957 $144–$5,248 $160
2024 $0 $1,042 $149–$5,650 $164
2025 $0 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Pfizer Inc. $5,600 2 payments
  2. Gilead Sciences, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,600 2 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2023
  1. TALZENNA $5,600 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2023
  1. Pfizer Inc. $1,900 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

51

Median for Medical Oncology: 414

Drug cost

$865

Median for Medical Oncology: $849,427

Branded share of claims

0%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tamoxifen Citrate Generic 21 $431
Letrozole Generic 19 $381
Dexamethasone Generic 11 $54

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 112 billing codes

Paid by Medicare

$1,031,414

Of which drugs: $978,398

Medicare patients

248

Average age 73

Services billed

44,219

132 women, 116 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Cancer 58%
Arthritis 33%
Chronic kidney disease 31%
Diabetes 24%
Ischemic heart disease 23%
Heart failure 21%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pembrolizumab, 1 mg J9271 Office 22 6,200 $250,071
Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 Office 26 4,685 $182,669
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 13 59 $8,197
Injection, bortezomib (velcade), 0.1 mg J9041 Office 11 420 $639
Injection, fluorouracil, 500 mg J9190 Office 21 185 $427
Injection, fosaprepitant, 1 mg J1453 Office 24 3,750 $401
Injection, irinotecan, 20 mg J9206 Office 11 182 $357
Injection, palonosetron hcl, 25 mcg J2469 Office 43 450 $311
Injection, leucovorin calcium, per 50 mg J0640 Office 20 66 $230
Injection, paclitaxel, 1 mg J9267 Office 12 2,112 $172

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

4 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record